Literature DB >> 11815469

Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?

John E Gerich1.   

Abstract

Insulin is released from the pancreas in a biphasic manner in response to a square-wave increase in arterial glucose concentration. The first phase consists of a brief spike lasting approximately 10 min followed by the second phase, which reaches a plateau at 2-3 h. It is widely thought that diminution of first-phase insulin release is the earliest detectable defect of beta-cell function in individuals destined to develop type 2 diabetes and that this defect largely represents beta-cell exhaustion after years of compensation for antecedent insulin resistance. In this article, the origins of these concepts are reviewed and recent evidence is presented suggesting that reductions in both phases of insulin release are equally early, that they precede insulin resistance other than that simply due to obesity, and that they therefore may represent the primary genetic risk factor predisposing individuals to type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815469     DOI: 10.2337/diabetes.51.2007.s117

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  72 in total

1.  Synapsins I and II are not required for β-cell insulin secretion: granules must pool their own weight.

Authors:  L S Satin
Journal:  Endocrinology       Date:  2012-05       Impact factor: 4.736

2.  Snapin mediates incretin action and augments glucose-dependent insulin secretion.

Authors:  Woo-Jin Song; Madhav Seshadri; Uzair Ashraf; Thembi Mdluli; Prosenjit Mondal; Meg Keil; Monalisa Azevedo; Lawrence S Kirschner; Constantine A Stratakis; Mehboob A Hussain
Journal:  Cell Metab       Date:  2011-03-02       Impact factor: 27.287

3.  Is the β-cell the key for remission of diabetes after bariatric surgery?

Authors:  Faidon Magkos; Samuel Klein
Journal:  J Physiol       Date:  2015-07-15       Impact factor: 5.182

4.  In Vitro Platform for Studying Human Insulin Release Dynamics of Single Pancreatic Islet Microtissues at High Resolution.

Authors:  Patrick M Misun; Burçak Yesildag; Felix Forschler; Aparna Neelakandhan; Nassim Rousset; Adelinn Biernath; Andreas Hierlemann; Olivier Frey
Journal:  Adv Biosyst       Date:  2020-01-29

5.  Syntaxin 4 up-regulation increases efficiency of insulin release in pancreatic islets from humans with and without type 2 diabetes mellitus.

Authors:  Eunjin Oh; Natalie D Stull; Raghavendra G Mirmira; Debbie C Thurmond
Journal:  J Clin Endocrinol Metab       Date:  2014-02-19       Impact factor: 5.958

Review 6.  Mechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins.

Authors:  Zhanxiang Wang; Debbie C Thurmond
Journal:  J Cell Sci       Date:  2009-04-01       Impact factor: 5.285

7.  First-Phase Insulin and Amylin after Bariatric Surgery: A Prospective Randomized Trial on Patients with Insulin Resistance or Diabetes after Gastric Bypass or Sleeve Gastrectomy.

Authors:  Rahel Nussbaumer; Anne Christin Meyer-Gerspach; Ralph Peterli; Thomas Peters; Christoph Beglinger; Sonja Chiappetta; Juergen Drewe; Bettina Wölnerhanssen
Journal:  Obes Facts       Date:  2020-11-17       Impact factor: 3.942

8.  Loss of beta cell function as fasting glucose increases in the non-diabetic range.

Authors:  I F Godsland; J A R Jeffs; D G Johnston
Journal:  Diabetologia       Date:  2004-07-13       Impact factor: 10.122

Review 9.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

10.  Unusually rapid beta-cell failure in a patient newly diagnosed with type 2 diabetes presenting acutely with unprovoked severe hyperglycaemic hyperosmolar state: a case report.

Authors:  Joey Yeoh; Judy Chien-Chun Huang; Harriet Cheng; Kenneth Ross Muir
Journal:  Cases J       Date:  2009-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.